APA (7th ed.) Citation

A, A., H, K., A, K., M, Y., Y, H., T, T., . . . H, K. (2026). Canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK-OPG-CTGF axis. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. https://doi.org/10.1016/j.pan.2026.05.006

Chicago Style (17th ed.) Citation

A, Adachi, et al. "Canagliflozin, a Sodium-glucose Cotransporter-2 (SGLT2) Inhibitor, Attenuates Pancreatic Fibrosis in Chronic Pancreatitis Through the AMPK-OPG-CTGF Axis." Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.] 2026. https://doi.org/10.1016/j.pan.2026.05.006.

MLA (9th ed.) Citation

A, Adachi, et al. "Canagliflozin, a Sodium-glucose Cotransporter-2 (SGLT2) Inhibitor, Attenuates Pancreatic Fibrosis in Chronic Pancreatitis Through the AMPK-OPG-CTGF Axis." Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.], 2026, https://doi.org/10.1016/j.pan.2026.05.006.